Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2022 | The latest updates on tafasitamab in DLBCL

Jason Westin • 4 Oct 2022
SOHO 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide R-CHOP Tafasitamab

Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the latest updates on the use of tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL) and ongoing clinical trials evaluating this agent. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.

More from Jason Westin

Rapcabtagene autoleucel for patients with first-line high-risk LBCL: Phase II interim results 1:05
Rapcabtagene autoleucel for patients with first-line high-risk LBCL: Phase II interim results
Jason Westin • 7 Dec 2025
Smart Stop: lenalidomide, tafasitamab, rituximab, & acalabrutinib ± chemo in newly diagnosed DLBCL 1:37
Smart Stop: lenalidomide, tafasitamab, rituximab, & acalabrutinib ± chemo in newly diagnosed DLBCL
Jason Westin • 7 Dec 2025
Classification systems for hematologic malignancies: the need to evolve and the role of AI 1:47
Classification systems for hematologic malignancies: the need to evolve and the role of AI
Jason Westin • 28 Sep 2025
AI in practice: gaps in knowledge and decentralized clinical trials 1:28
AI in practice: gaps in knowledge and decentralized clinical trials
Jason Westin • 28 Sep 2025

Related Videos

Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL 2:11
Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL
Reid Merryman • 8 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals